Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of subcutaneous AHB-137 in healthy volunteers and HBeAg-negative chronic hepatitis B patients on nucleos(t)ide analogue therapy
CTR20232098Phase 2Completed
- Sponsor
- HaoBo Medicine
- Start
- Aug 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AHB-137 in Chronic Hepatitis B (CHB), sponsored by HaoBo Medicine. Started Aug 2023; status: completed.
02
Drugs
AHB-137
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20232098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232098.